Follow The Filings

RXRX Recursion Pharmaceuticals Inc.

Health Care, filed as Recursion Pharmaceuticals Inc (COMMON STOCK), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 1.0%
  • $152M
  • 1 add

In 2026 Q2 Cathie Wood added to Recursion Pharmaceuticals.

Who owns this now

Largest portfolio weights among holders, up to 1.0% (Cathie Wood, Ark Investment Management). Not free-float ownership.

  1. Cathie Wood Add 0.98%

Who owns RXRX

Sorted by value, long equity only, as of 2026 Q2.

History
Cathie Wood, Ark Investment Management 0.98%, was 0.96% Add +2.8% 41,337,632 $152M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by RXRX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All RXRX insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $8.2M sold by 6 insiders under 10b5-1 plans
  1. Blake Borgeson Director
    Planned sale
    $242K 50,000 shares at $4.84 0.8% of stake
    Traded Oct 6 Filed Oct 7
    ↗
  2. Robert Hershberg Director
    Planned sale
    $125K 25,000 shares at $5.00 13% of stake
    Traded Oct 6 Filed Oct 7
    ↗
  3. Najat Khan CEO
    Planned sale
    $79K 22,408 shares at $3.52 1.1% of stake
    Traded Sep 8 Filed Sep 10
    ↗
  4. Blake Borgeson Director
    Planned sale
    $100K 30,000 shares at $3.34 0.5% of stake
    Traded Sep 1 Filed Sep 2
    ↗
  5. Blake Borgeson Director
    Planned sale
    $98K 30,000 shares at $3.25 0.5% of stake
    Traded Aug 4 Filed Aug 6
    ↗
  6. Blake Borgeson Director
    Planned sale
    $159K 40,000 shares at $3.96 0.6% of stake
    Traded Jul 7 Filed Jul 9
    ↗
  7. Namandje Bumpus Director
    Planned sale
    $13K 3,963 shares at $3.18 3% of stake
    Traded Jun 18 Filed Jun 22
    ↗
  8. Najat Khan CEO
    Planned sale
    $84K 23,588 shares at $3.58 1.1% of stake
    Traded Jun 5 Filed Jun 5
    ↗
  9. Christopher Gibson Director
    Planned sale
    $145K 40,000 shares at $3.62 4.3% of stake
    Traded Jun 5 Filed Jun 5
    ↗
  10. Namandje Bumpus Director
    Planned sale
    $16K 4,386 shares at $3.54 9.2% of stake
    Traded Jun 3 Filed Jun 4
    ↗
  11. Blake Borgeson Director
    Planned sale
    $110K 30,000 shares at $3.68 0.5% of stake
    Traded Jun 2 Filed Jun 4
    ↗
  12. Christopher Gibson Director
    Planned sale
    $123K 40,000 shares at $3.08 4.3% of stake
    Traded May 22 Filed May 27
    ↗
  13. Christopher Gibson Director
    Planned sale
    $135K 40,000 shares at $3.37 4.1% of stake
    Traded May 7 Filed May 8
    ↗
  14. Blake Borgeson Director
    Planned sale
    $106K 30,000 shares at $3.52 0.5% of stake
    Traded May 5 Filed May 7
    ↗
  15. Christopher Gibson Director
    Planned sale
    $144K 40,000 shares at $3.61 4.2% of stake
    Traded Apr 22 Filed Apr 24
    ↗

Also filed in the last 12 months, not counted as buying or selling: 24 share withholdings for taxes, 23 stock grants, 16 conversions, 5 gifts, and 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 11 shown.

Filed Form Detail Links
424B5 Filing Doc
424B5 Filing Doc
8-K 1.01,2.02,7.01,8.01,9.01 Filing Doc
8-K 1.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.07 Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $44.58M $58.84M $74.68M
Gross profit * $1.99M $13.6M $3.73M
Gross margin * 4.5% 23.1% 5.0%
Net income -$328.07M -$463.66M -$644.76M
Net margin * -736.0% -788.0% -863.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $438.14M $714.27M $812.84M
Total non-current assets * $215.56M $734.33M $661.28M
Total assets $0.654B $1.45B $1.47B
Total current liabilities $93.17M $187.47M $147.71M
Total non-current liabilities * $97.09M $226.34M $195.56M
Total equity $0.463B $1.03B $1.13B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$287.78M -$359.17M -$371.81M
Cash from investing -$10.23M $260.06M -$16.87M
Cash from financing $140.13M $304.12M $521.53M
Net change in cash -$157.69M $201.6M $150.9M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.